Ipilimumab has efficacy in metastatic Merkel Cell Carcinoma: a case series of five patients

Abstract

Immunotherapy with immune checkpoint blockers such as the CTLA-4 antibody ipilimumab and PD-1 antibodies has revolutionized oncological treatment options¹. MCC is an immunogenic tumor and the efficacy of PD-1 blockade has recently been demonstrated^2,3,4. Here, we present a retrospective analysis of five patients with metastatic MCC individually treated with ipilimumab between 2012 and 2015. Administration of four cycles (3 mg/kg every three weeks) was planned. Informed consent was obtained from all patients. Patient characteristics are depicted in table 1. All patients had received previous surgical and radiation therapy before initiation of ipilimumab.

This article is protected by copyright. All rights reserved.

http://ift.tt/2mhu2SM